PeptidePedia The community reference

Talk:Contraindications of incretin therapy

Discussion page·2 threads·no archives

This article is within the scope of the clinical practice working group.

This is the discussion page for the article Contraindications of incretin therapy. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Contraindication is a labelling conceptResolved

The concept belongs to approved products. Saying so prevents the article being read as a safety assessment of research material. — LabelLibby (talk) 09:45, 20 February 2026 (UTC)

And it explains why the clinical information is still worth having, with its provenance stated. ✓ Done — ScopeSeverin (talk) 13:20, 20 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Renal caution is indirectDone

Worth distinguishing renal clearance of the drug, which is not the issue for most of this class, from volume depletion, which is. — eGFR_Esme (talk) 10:15, 13 May 2026 (UTC)

Stated as an indirect mechanism in the table note. ✓ Done — ClinicCorrespondent (talk) 13:50, 13 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 13 May 2026, by ClinicCorrespondent. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).